Drug extends survival in lung cancer patients
Drug extends survival in lung cancer patients: J&J
Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung cancer that has specific epidermal growth factor receptor mutations.
Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...
The other day, Dame Esther Rantzen announced some wonderful news. In an article she’d written for a national newspaper, ...
Dame Esther responded after a columnist tried to use her own cancer experience as an argument against assisted dying.
Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for ...
China National Medical Products Administration (NMPA) has granted acceptance and priority review for the new drug application ...
Limited (HUTCHMED) (HCM) announced that the New Drug Application (NDA) for the combination of ORPATHYS(savolitinib) ...
Cilag’s Rybrevant in combo with Lazcluze for first-line treatment of patients with EGFR-mutated advanced NSCLC: Beerse, Belgium Tuesday, Dec ...
Belgium: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the European Commission (EC) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback